https://la-newswire.com/wp-content/uploads/2023/07/new-vaccine.jpeg
697
465
Merci
Merci
https://la-newswire.com/wp-content/uploads/2021/09/Merci-96x96.jpg
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19…